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Abstract
Background: Drug-resistant Providencia rettgeri producing metallo-β-lactamase and 16S rRNA methylase has
been reported in several countries. We analyzed P. rettgeri clinical isolates with resistance to carbapenems and
aminoglycosides in a hospital in Nepal.
Methods: Five clinical isolates of multidrug-resistant P. rettgeri were obtained in a hospital in Nepal. Antimicrobial
susceptibilities were determined using the microdilution method and entire genomes were sequenced to
determine drug-resistant genes. Epidemiological analysis was performed by pulsed-field gel electrophoresis.
Results: Four of the 5 isolates were resistant to carbapenems (imipenem and meropenem), with MICs ≥16 mg/L,
with the remaining isolate showing intermediate resistance to imipenem, with an MIC of 2 mg/L and susceptibility
to meropenem with an MIC ≤1 mg/L. All 5 isolates had blaVEB-1. Of the 4 carbapenem-resistant strains, 3 had
blaNDM-1 and 1 had blaOXA-72. All isolates were highly resistant to aminoglycosides (MICs ≥1,024 mg/L) and harbored
armA. As the result of pulsed-field gel electrophoresis pattern analysis in the 5 P. rettgeri isolates, 4 had identical
PFGE patterns and the fifth showed 95.7% similarity.
Conclusions: This is the first report describing multidrug-resistant P. rettgeri strains harboring blaNDM-1 or blaOXA-72
and armA isolated from patients in Nepal.
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Background
Providencia rettgeri has been associated with hospital
acquired infections, including catheter-related urinary
tract infections, bacteremia, skin infections, diarrhea, and
gastroenteritis [1,2]. To date, there have been 5 reports of
P. rettgeri isolates harboring metallo-β-lactamase (MBL)
encoding genes, including IMP-type MBL producers in
Japan [3,4]; VIM-type MBL, PER-1 extended-spectrum β-
lactamase (ESBL) and 16S rRNA methylase ArmA in
Korea [5]; and NDM-type MBL in Israel [6] and Brazil [7].
NDM-type MBL was initially identified in Klebsiella
pneumoniae and Escherichia coli in 2009 in Sweden [8].
Since then, NDM-1-producing Enterobacteriaceae have
been isolated in various parts of the world [9,10].
Exogenously acquired 16S rRNA methylase genes re-
sponsible for very high levels of resistance to various
aminoglycosides are widely distributed among Entero-
bacteriaceae and glucose-nonfermentative microbes [11].
Gram-negative pathogens producing 16S rRNA methylase
ArmA have been isolated in various countries [11].
Although co-production of several resistance determi-
nants is not rare in Enterobacteriaceae [12-16], it is less
common in P. rettgeri [5]. We describe here P. rettgeri
clinical isolates from Nepal that produce carbapenemase
(NDM-1 or OXA-72) and 16S rRNA methylase (ArmA).
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Table 1 Summary of the characteristics of the 5 P. rettegeri strains, including antimicrobial resistance profiles and resistant genes
Strains Tissue
sources
Infection MIC (mg/L) Antibiotics resistant genes
PIP TZP CAZ FEP IPM DPM MEM ATM ABK AMK GEN CIP CST FOF TIG
IOMTU1 Pus SSI 1,024 512 >1,024 64 32 16 64 1,024 >1,024 >1,024 >1,024 128 >128 512 4 blaNDM-1, blaOXA-10, blaVEB-1, blaTEM-1, blaADC-67,
armA, aadA1, aadA2
IOMTU4 Sputum NLRTI 1,024 128 >1,024 256 16 16 32 1,024 >1,024 >1,024 >1,024 >256 >128 512 4 blaOXA-72, blaOXA-10, blaVEB-1, blaTEM-1, blaADC-67,
armA, aadA1
IOMTU91 Sputum NLRTI >1,024 1,024 >1,024 1,024 64 32 64 1,024 >1,024 >1,024 >1,024 256 128 128 4 blaNDM-1, blaOXA-10, blaVEB-1, blaTEM-1, blaADC-67,
armA, aadA1
IOMTU94 Pus SSI 1,024 4 >1,024 256 2 1 1 >1,024 1,024 1,024 >1,024 256 >128 1,024 4 blaOXA-10, blaVEB-1, blaTEM-1, blaADC-67,
armA, aadA1
IOMTU99 Sputum NLRTI >1,024 512 >1,024 128 64 32 64 1,024 >1,024 >1,024 >1,024 >256 >128 1,024 4 blaNDM-1, blaVEB-1, blaOXA-10, blaTEM-1, blaADC-67,
armA, aadA1
SSI, surgical site infection; NLRTI, nosocomial lower respiratory tract infection PIP, piperacillin; TZP, piperacillin/tazobactam; CAZ, ceftazidime; FEP, cefepime; IPM, imipenem; DPM, doripenem; MEM, meropenem; ATM,





















Five P. rettgeri clinical isolates were obtained from May
to July 2012 from 5 patients at Tribhuvan University
Teaching Hospital in Kathmandu, Nepal. Three isolates
were from sputum and 2 from pus at surgical sites.
Samples were obtained as part of standard patient care.
Phenotypical identification [17] was confirmed by API
32GN (BioMérieux, Mercy l'Etoile, France) and 16S rRNA
sequencing (1,497 bp) [18,19].
Antimicrobial susceptibilities
MICs were determined using the microdilution method,
according to the guidelines of the Clinical Laboratory
Standards Institute (CLSI) [20]. Breakpoints to antibiotics
were determined. The modified Hodge test, the merope-
nem-sodium mercaptoacetic acid double-disk synergy test
(Eiken Chemical, Tokyo, Japan) and E-test (imipenem/
EDTA) (AB Biodisk, Solna, Sweden) were performed.
Entire genome sequencing
The entire genomes of these isolates were extracted and
sequenced by MiSeq (Illumina, San Diego, CA). CLC
genomics workbench version 5.5 (CLC bio, Tokyo,
Japan) was used for de novo assembly of reads and to
search for 923 drug-resistance genes, including genes
encoding β-lactamases, 16S rRNA methylases and
aminoglycoside-acethyl/adenylyltransferases; point muta-
tions in the gyrA, parC and pmrCAB operons; and point
mutations in the fos genes, including fosA, fosA2, fosA3,
fosC and fosC2.
Pulsed-field gel electrophoresis (PFGE) and southern
hybridization
PFGE analysis was performed as described [3]. An
813 bp probe for blaNDM-1 was synthesized by PCR
amplification using the primers 5′-atggaattgcccaatattatg-
cac-3′ (forward) and 5′-tcagcgcagcttgtcggccatgcggg-3′
(reverse), and a 780 bp probe for blaOXA-72 was synthe-
sized using the primers 5′-agtttctctcagtgcatgttcatctat-3′
(forward) and 5′-agaaccagacattccttctttcatttc-3′ (reverse).
Southern hybridization to detect blaNDM-1 and blaOXA-72
was performed using these probes, which were detected
using DIG High Prime DNA labeling and detection
starter kit II (Roche Diagnostics, Mannheim, Germany).
Nucleotide sequence accession numbers
The nucleotide sequences surrounding blaNDM-1 and
blaOXA-72 have been deposited in GenBank with the ac-
cession number AB828598 and AB857844, respectively.
Ethical approval
The study protocol was reviewed and approved by the
Institutional Review Board of the Institute of Medicine,
Tribhuvan University (ref. 6-11-E) and the Biosafety Com-




Four of the 5 isolates were resistant to carbapenems
(doripenem, imipenem and meropenem) and pipera-
cillin/tazobactam, whereas the fifth was susceptible to
piperacillin/tazobactam, doripenem and meropenem and
showed intermediate resistance to imipenem (Table 1).
All 5 isolates were highly resistant to cephalosporins
(ceftazidime and cefepime), aztreonam, aminoglycosides
(arbekacin, amikacin and gentamicin), ciprofloxacin, co-
listin and fosfomycin, and all 5 showed intermediate
resistance to tigecycline. The four isolates resistant to
carbapenems were negative with the modified Hodge
test, but three of the four isolates were positive with the
meropenem-sodium mercaptoacetic acid double-disk
synergy test and E-test/EDTA.
Drug-resistant genes
All 5 isolates tested had several genes associated with
β-lactam and aminoglycoside-resistance (Table 1). These
isolates had blaVEB-1, blaOXA-10, blaTEM-1, blaADC-67
(ampC), armA and aadA1; 3 had blaNDM-1; and 1 had
blaOXA-72. None of these isolates had any other β-
lactamase encoding genes, including the class A genes
blaSHVs and blaCTX-Ms; the class B genes blaAIM, blaDIM,
blaFIM, blaGIM, blaIMPs, blaINDs, blaKHM, blaSIM, blaSMB,
blaSPM, blaTMBs, and blaVIMs; or the class D gene
blaOXAs except for blaOXA-10 and blaOXA-72. None had
other genes encoding 16S rRNA methylases or amino-
glycoside acetyl/adenylyltransferases. All 5 isolates had
point mutations in the quinolone-resistance-determining
regions of gyrA and parC, with amino acid substitutions
of S83I and D87E in GyrA and S80I in ParC, but none
had any mutations in the pmrCAB operon and fos genes.
All sequences of the drug-resistant genes tested were
identical to those registered in GenBank.
Figure 1 PFGE profiles obtained following SfiI digestion of
P. rettgeri chromosomes.
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PFGE and southern hybridyzation
Of the 5 P. rettgeri isolates, 4 had identical PFGE patterns
and the fifth showed 95.7% similarity (Figure 1). Three of
these isolates had a plasmid harboring blaNDM-1 and one
had a plasmid harboring blaOXA-72, with plasmid sizes
ranging from 9.42 to 23.1 kbp (data not shown).
Genomic structures surrounding blaNDM-1 and blaOXA-72
The genetic environments surrounding blaNDM-1 (Acces-
sion no. AB828598) was blaNDM-1-bleMBL-trpF-dsbC-cutA1.
All 3 isolates harboring blaNDM-1 (IOMTU1, 91 and 99)
had the same genetic environments. The blaOXA-72
gene was flanked by conserved inverted repeats at the
XerC/XerD binding sites [21], indicating mobilization
by site-specific recombination mechanisms. The rep1
gene was located downstream of blaOXA-72 (Accession
no. AB857844).
Discussion
The relatively high MICs to piperacillin/tazobactam and
carbapenems of the five P. rettgeri isolates were likely
due to the presence of blaNDM-1 or blaOXA-72. The
enzymatic activities of metallo-β-lactamases, including
NDM-1, were not inhibited by tazobactam [22], a β-
lactamase inhibitor, in agreement with the MIC profiles
of these isolates to piperacillin/tazobactam. The high
MICs of all 5 isolates to ceftazidime, cefepime and aztre-
onam were likely due to the presence of blaVEB-1 [23],
and the presence of armA in these isolates was likely
associated with their extremely high resistance to all
aminoglycosides tested [11]. Point mutations in the quin-
olone-resistance-determining regions of gyrA and parC
have been associated with high resistance to quinolones
[24]. Point mutations in pmrCAB operon have been asso-
ciated with the resistance of Acinetobacter spp. [25] and
Pseudomonas aeruginosa [26] to polymxyin and colistin;
and the presence of fos genes, including fosA, fosA2, fosA3,
fosC and fosC2, has been associated with resistance to
fosfomycin in Gram-negative bacteria [27-29].
Plasmids containing blaNDM-1 or blaOXA-72 may be
disseminated among Gram-negative pathogens in Nepal.
The genetic environments surrounding blaNDM-1 in our
P. rettgeri strains (blaNDM-1-bleMBL-trpF-dsbC-cutA1)
were also observed in other plasmids, including A. bau-
mannii plasmid pAbNDM-1 from China (Accession no.
JN377410), Citrobacter freundii plasmid pYE315203
from China (Accession no. JX254913), E. coli plasmid
pNDM102337 from Canada (Accession no. JF714412),
K. pneumoniae plasmid pKP-NCGM18-1 from Nepal
(Accession no. AB824738) [30], K. pneumoniae plasmids
pKPX-1, pKPN5047 and pNDM-HN380 from China
(Accession nos. AP012055, KC311431 and JX104760,
respectively), and P. rettgeri plasmid pFR90 (Accession no.
JQ362415) from China. In addition, the genetic structures
of OXA-72 producing Acinetobacter spp [31-34] and K.
pneumoniae (Accession no. JX268653 and AB825955
deposited in 2012 and 2013, respectively) had the
same genetic structure (blaOXA-72-rep1) as our strain
of P. rettgeri.
Conclusions
To our knowledge, this is the first report describing P.
rettgeri strains harboring blaNDM-1 or blaOXA-72 and
armA isolated from patients in Nepal. These 5 strains
were highly resistant to both β-lactams and aminoglyco-
sides and expanded in a clonal manner in the hospital.
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